<![CDATA[Toxicity Management of PI3K Pathway Inhibitors in HR+/HER2− mBC]]>

Summary

Article discusses toxicity management considerations for PI3K pathway inhibitors alpelisib and capivasertib in hormone receptor-positive/HER2-negative metastatic breast cancer, with clinicians noting alpelisib's hyperglycemia and rash side effects while capivasertib may present lower glucose risk.